We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 574

Listing patents against combination drugs in Canada ? Changes coming

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in

Statements in a generic’s Product Monograph were not found to amount to an inducement to infringe

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

The Court has allowed a motion to strike portions of an application pursuant to Paragraph 6(5)(b) of the PM(NOC) Regulations. The generic respondent

Although moot, Minister of Health is found to be wrong to issue NOCs to generic companies without first requiring them to serve a notice of allegation

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

Actelion has persuaded the Court to quash the NOCs provided to two generic companies after they were awarded by the Minster of Health. However, the

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • October 16 2014

Canada Introduction 'Personalized medicine', in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs

Canada PM(NOC) decision: Federal Court judge criticizes “very sketchy” disclosure in a CIALIS patent

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • March 30 2015

On February 2, 2015 Justice de Montigny of the Federal Court released his judgment and reasons in Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC

Teva Canada Limited v. sanofi-aventis Canada Inc.

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 16 2011

This was an appeal of the decision of the Judge, upholding the decision of the Prothonotary, to strike out Teva's claim to permanent loss of market share in an action brought pursuant to section 8 of the NOC Regulations

Pleadings for disgorgement of profits and for an accounting of profits in s.8 damages not struck in Ontario court

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 1 2012

In this case, Apotex has claimed damages in Ontario Court pursuant to, inter alia, section 8 of the NOC Regulations. Lilly brought a motion to strike out parts of Apotex’ statement of claim

The Myriad decision: what is the impact?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013

Federal Court upholds validity of patent for escitalopram (CIPRALEX)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 19 2013

Apotex Inc. (“Apotex”) brought an action for impeachment seeking a declaration that Lundbeck’s Canadian Patent No. 1,339,452 (the “’452 Patent”) is

Canada and the EU successfully conclude CETA: what it means to the pharmaceutical industry

  • McCarthy Tétrault LLP
  • -
  • Canada, European Union
  • -
  • September 30 2014

On September 26, 2014, Prime Minister Harper announced that Canada and the European Union have successfully concluded negotiations on a new trade